Publications Repository 2010

Bagratuni T et al. (2010) XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments. Blood 2010; 116(2): 250-253
Boyd, KD et al. (2010) High expression levels of the mammalian target of rapamycin inhibitor DEPTOR are predictive of response to thalidomide in myeloma. Leukemia & Lymphoma 2010; 51(11): 2126-2129
Dickens, NJ et al. (2010) Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome. Clinical Cancer Research; 2010 16: 1856-1864.
Morgan GJ et al. (2010) First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet; 2010; 376: 1989-1999.
Ross, FM et al. (2010) The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance. Haematologica. 2010 Jul; 95(7): 1221–1225.
Tod, A & Joanne, R (2010) Overcoming delay in the diagnosis of lung cancer: a qualitative study. Nursing Standard; Apr 2010; vol. 24 (no. 31); p. 35-43
Walker BA et al. (2010) A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value Blood 2010; 116(15): 56-65.